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Edited by Varda RotterAbstract Expression of p53-target gene EI24/PIG8 is lost in
invasive breast cancers, suggesting that EI24/PIG8 is a tumor
suppressor that prevents tumor spreading, and partially mediates
p53-attributed tumor suppressor activity. EI24/PIG8 also has
pro-apoptotic activity indicating that loss of EI24/PIG8 may
modulate sensitivity to chemotherapy. Here it is demonstrated
that suppression of EI24/PIG8 in ﬁbroblasts and breast cancer
cells signiﬁcantly inhibits the apoptotic response to etoposide
treatment. These ﬁndings suggest that loss of EI24/PIG8 con-
tributes signiﬁcantly to resistance of cells to chemotherapeutic
agents that function through p53, and identify the EI24/PIG8
status as a potentially new prognostic marker of chemotherapy
responsiveness.
 2007 Federation of European Biochemical Societies.
Published by Elsevier B.V. All rights reserved.
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EI24 (etoposide-induced 2.4 kb transcript) was ﬁrst isolated
by diﬀerential display in 3T3 ﬁbroblasts as an etoposide-
induced gene associated with apoptosis by this drug [1]. Etopo-
side is a chemotherapeutic agent which inhibits topoisomerase
II and is often used in combination regimens to treat breast
cancer and other carcinomas [2]. The human PIG8 gene
(p53-induced gene 8) was discovered in screens of approxi-
mately 7200 mRNA transcripts as one of 14 genes upregulated
by restoring p53-dependent apoptotic activity in a p53-null cell
line [3]. Murine EI24 and human PIG8 sequences are 98%
homologous [4]. Murine EI24 is also 52% similar to an
open reading-frame found in Caenorhabditis elegans suggesting
an important biological role for this highly-conserved gene
[4].
Invasive cervical cancers and breast carcinomas frequently
exhibit loss of heterozygosity at 11q23, the chromosomal loca-
tion of the PIG8 gene [5–9]. Among four genes examined at
this location in 41 aggressive breast tumors, EI24/PIG8 was*Corresponding author. Fax: +1 617 638 5837.
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doi:10.1016/j.febslet.2007.10.046the most often altered (by mutation, aberrant splicing, or dele-
tion) [10]. Reduced EI24/PIG8 protein expression has also
been documented in invasive ductal carcinomas, but not carci-
noma in situ suggesting that EI24/PIG8 serves to prevent
tumor invasion [11].
Studies to date have suggested a wide range of possible roles
for EI24/PIG8 in apoptosis, some of which may possibly ex-
plain the correlation between EI24/PIG8 status and tumor
invasiveness. EI24/PIG8 is regulated by p53, a critical trans-
cription factor that is a central mediator of the apoptotic re-
sponse to DNA-damaging agents. EI24/PIG8 also causes
growth arrest and apoptosis when ectopically over-expressed
[4]. Conversely, depletion of EI24/PIG8 by antisense oligode-
oxynucleotides results in suppression of apoptosis in response
to the pro-apoptotic retinoid, CD437/AHPN [12]. p53 binds
speciﬁcally to a p53-response element in the mouse gene
promoter although the human EI24/PIG8 promoter has not
yet been characterized. These data suggest that EI24/PIG8
functions downstream of p53, and that some of the apoptotic
potential of p53 is transduced through EI24/PIG8.
Importantly, loss of EI24/PIG8 in tumor cells may have addi-
tional adverse consequences for the host, because the eﬃcacy
of etoposide and other chemotherapeutic drugs is at least
partially dependent on a p53-dependent apoptotic response
[13–15].
We tested a potential role for EI24/PIG8 in modulating sen-
sitivity to etoposide as a representative DNA damage-inducing
agent used in chemotherapy, to assess the possibility of an
important eﬀector role for EI24/PIG8 as a p53-regulated
pro-apoptotic gene [1,16]. Our ﬁndings suggest a novel role
for EI24/PIG8 in the clinically important phenomenon of che-
motherapy resistance.2. Materials and methods
2.1. Cell culture and siRNA transfections
NIH 3T3 murine ﬁbroblasts were grown in DMEM with 10% (v/v)
donor calf serum, and MCF-7 human breast cancer cells were grown in
DMEM with 10% (v/v) fetal bovine serum, at 37 C in humidiﬁed air
with 5% CO2. Cells were transfected with Lipofectamine Transfection
Reagent and allowed to recover for 24 h before further treatment.
Fluorescein-tagged siRNA oligo was obtained from Qiagen. Prede-
signed EI24/PIG8 and negative control siRNA oligos were purchased
from Ambion with the sequence 5 0 CCACGUAUUGUUAGUAGA-
ATT 3 0 (murine EI24 siRNA) and 5 0 GGAAUCAAAGACUCCAU-
CUTT 3 0 (human PIG8 siRNA). Etoposide (Sigma) was prepared as
a DMSO solution for each experiment.blished by Elsevier B.V. All rights reserved.
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Cell cycle distribution and apoptosis were analyzed 24 h after treat-
ment with etoposide (0.4 mM). Cells permeabilized in 70% ethanol and
stained with propidium iodide (PI) (25 lg/ml) and RNase A (50 lg/ml)
were analyzed by ﬂow cytometry, collecting 20,000 cells/sample.
Apoptotic cells were identiﬁed as a distinct sub-G1 peak in logarithmic
plots of PI ﬂuorescence intensity generated using Cellquest Pro soft-
ware.
2.3. Terminal deoxynucleotidyl transferase biotin-dUTP nick end
labeling (TUNEL) reaction
Cells were grown on Lab-Tek chamber slides, transfected with con-
trol siRNA or siEI24/PIG8 oligo, and treated with DMSO or etopo-
side (0.4 mM). Apoptosis was assessed using the TMR red in situ
cell death detection kit (Roche). Brieﬂy, cells were ﬁxed with 4% para-
formaldehyde, permeabilized with 0.1% Triton X-100 in 0.1% sodium
citrate, and DNA strand breaks were labeled by terminal deoxynucleo-
tidyl transferase. Slides were mounted with DAPI and DabCo anti-
fade solution and observed using a Nikon Eclipse E800 microscope,
digital camera, and Metasystems FISH software. The total number
of cells in each ﬁeld of view was recorded based on DAPI-positive
(blue) nuclei. The fraction of these that were TUNEL-positive (red)
was then determined. Cells in at least ﬁve randomly selected ﬁelds of
view were counted for each condition.2.4. Real time PCR
RNA was harvested from cells 24 h after exposure to etoposide
(0.4 mM) and cDNA was synthesized using an Invitrogen Thermo-
script Kit according to the manufacturer’s instructions. SYBR Green
master mix was used to quantitate product using Applied Biosystem’s
7500 Fast real-time PCR system. The murine b-actin primers used as
an internal control were: 5 0 AGCCATGTACGTAGCCATCC 3 0 and
5 0 CTCTCAGCTGTGGTGGTGAA 3 0. The murine EI24 primers
spanning exons 9–10 were: 5 0 TCTCTTCCCCATCCATCTT 3 0 and
5 0 TAACGTAACGACACTCCTTTC 3 0. Human b-actin primers used
as an internal control were: 5 0 TCCCTGGAGAAGAGCTACGA
3 0 and 5 0 AGCACTGTGTTGGCGTACAG 3 0. The human PIG8
primers were: 5 0 CGGTAACAGCCCGAATTATC 3 0 and 5 0
GGCTTCCTCCCTGATACCTC 3 0.ig. 1. Suppression of EI24/PIG8 induction in NIH 3T3 cells by
iRNA reduces their sensitivity to etoposide. siRNA targeting EI24/
IG8 mRNA (siEI24/PIG8), or negative control siRNA, and ﬂuores-
ein-tagged siRNA were transfected into NIH 3T3 cells (10:1 ratio).
he ﬂuorescein signal was clearly visible inside the cells after
ransfection. After 24 h transfected cells were treated for an additional
4 h with etoposide (0.4 mM) or DMSO (vehicle). Cells were analyzed
y two methods, qRT PCR (A) and ﬂow cytometry (B and C). (A)
NA was harvested, cDNA was synthesized and qRT PCR, using
I24/PIG8-speciﬁc primers, was used to quantify the amount of EI24/
IG8 mRNA. mRNA expression was measured relative to an internal
ontrol (endogenous b-actin) and reported as relative values normal-
ed to control siRNA/DMSO-treated sample. Data are expressed as
he means ± S.E.M (n P 3). P-values were calculated using Student’s
-test. (B and C) PI-staining of nuclear DNA was used to examine cell
ycle proﬁles. To facilitate quantiﬁcation of relative fractions of cells in
1 (M1), S (M3), or G2/M (M2) phases, cells were assayed on a linear
uorescence scale, while sub-G1 (apoptotic) populations were assayed
n a logarithmic scale. The results from one of two independent
xperiments yielding equivalent outcomes are shown.3. Results
3.1. Knockdown of EI24/PIG8 suppresses etoposide-induced
apoptosis in NIH 3T3 cells
To test the role of EI24/PIG8 in chemotherapy resistance,
we used NIH 3T3 cells, the line in which EI24/PIG8 was orig-
inally discovered as a p53-regulated, apoptosis-associated
gene. To determine whether loss of EI24/PIG8 aﬀected the
capacity of the cells to undergo apoptosis in response to etopo-
side, an siRNA targeting E124/PIG8, or control siRNA, was
transfected into vehicle control-(DMSO) and etoposide-trea-
ted cells. The EI24/PIG8-speciﬁc siRNA (siEI24/PIG8) signif-
icantly and speciﬁcally suppressed EI24/PIG8 mRNA levels,
compared to cells transfected with a control siRNA, as assayed
by quantitative qRT PCR (Fig. 1A). Flow cytometry was then
used to measure the fraction of apoptotic cells by determining
the percentage of cells with sub-G1 DNA content. As ex-
pected, treatment with etoposide induced apoptosis in cells
transfected with control siRNA, compared with similarly
transfected cells treated with vehicle (DMSO) alone (Fig. 1B
and C). In contrast, no induction of apoptosis was observed
in response to etopside treatment in those cells transfected with
siEI24/PIG8. While a slight increase in baseline levels of apop-
tosis was observed between siRNA control- and siEI24/PIG8-
transfected cells, likely due to non-speciﬁc RNAi-associated
toxicity, cells in which EI24/PIG8 mRNA levels had beenF
s
P
c
T
t
2
b
R
E
P
c
iz
t
t
c
G
ﬂ
o
e
5442 C.N. Mork et al. / FEBS Letters 581 (2007) 5440–5444knocked down were clearly protected from etoposide-induced
apoptosis, with no signiﬁcant diﬀerences in the percentage of
cells exhibiting sub-G1 levels of DNA content between DMSO
and etoposide-treated cells (35.9% and 36.6%).
To conﬁrm that NIH 3T3 cells lacking EI24/PIG8 were less
sensitive to etoposide, the TUNEL reaction, which detects
double-stranded DNA breaks and nicks, speciﬁcally identify-
ing apoptotic cells, was employed. Signiﬁcantly fewer tetram-
ethylrhodamine (TMR) red-positive cells were present after
etoposide treatment of cell cultures in which EI24/PIG8 levels
had been suppressed by siRNA, compared with cells transfec-
ted with control siRNA. Approximately 12.6% of control siR-
NA-transfected cells treated with etoposide underwent
apoptosis, compared to fewer than 1% of cells treated with
DMSO (Fig. 2). In contrast, only 2.7% of siEI24/PIG8-trans-
fected cells treated with etoposide underwent apoptosis with
similar basal levels of apoptosis (<1%) in DMSO-treated cells.
Thus, etoposide-dependent apoptosis was reduced almost 5-
fold in cells in which EI24/PIG8 mRNA levels were eﬀectively
suppressed.3.2. MCF-7 breast cancer cells express EI24/PIG8 protein
Next, we wished to assess the relevance of EI24/PIG8 to
chemotherapy resistance in p53-competent MCF-7 human
breast cancer cells since loss of EI24/PIG8 has been estab-
lished in this type of cancer. In addition, it was necessary to
establish whether EI24/PIG8 serves the same function in
malignant cells. However, before initiating these experiments
it was ﬁrst necessary to ascertain that EI24/PIG8 is expressed
in MCF-7 cells. For this purpose, MCF-7 cells were grown on
chamber slides, ﬁxed, blocked, and stained with the EI24/
PIG8 antibody, as previously described [11]. Incubation with
a ﬂuorescein isothyocyanate (FITC)-conjugated secondary
antibody allowed detection of EI24/PIG8 protein in cells by
ﬂuorescence microscopy. MCF-7 cells were found to express
etoposide-inducible levels of cytoplasmic EI24/PIG8
(Fig. 3A), consistent with its reported presence in the endo-
plasmic reticulum [11]. Additionally, sequence analysis showed
no mutations in EI24/PIG8 cDNA cloned from these cells
(data not shown).Fig. 2. Suppression of EI24/PIG8 induction in NIH 3T3 cells reduces
their sensitivity to etoposide as assayed by TUNEL reactivity. Cells
transfected with EI24/PIG8 siRNA or a negative-control siRNA were
incubated for 24 h, with or without etoposide, and stained for DNA
breaks. TMR-red (TUNEL)-positive cells were observed only in the
populations transfected with control siRNA and treated with etopo-
side (0.4 mM). (A) Representative experiment showing apoptotic eﬀect
of etoposide on normal and EI24/PIG8-depleted cells. (B) Quantiﬁca-
tion of multiple ﬁelds of view and demonstrated statistical signiﬁcance.
On average, over 1000 DAPI-positive cells were counted for each
reaction condition. Data are expressed as the means ± calculated
S.E.M (average number of cells counted for each condition = 1338). P-
values were calculated using Student’s t-test.3.3. Suppression of EI24/PIG8 mRNA levels inhibits etoposide-
induced apoptosis in MCF-7 cells
Analysis of EI24/PIG8 transcript levels by qRT PCR
showed that transfection of siEI24/PIG8 (optimally designed
for human EI24/PIG8 transcripts) strongly suppressed
etoposide-dependent induction of EI24/PIG8 mRNA by
approximately 5-fold compared to levels in control siRNA-
transfected cells (Fig. 3B).
TUNEL assays were performed in control siRNA-transfec-
ted cells and in EI24/PIG8-depleted cells, in the absence or
presence of etoposide. As shown in Fig. 3C and D, 32% of con-
trol siRNA-transfected cells treated with etoposide underwent
apoptosis, up from basal levels of 1.5% in the presence of
DMSO. In contrast, only 10.5% of siEI24/PIG8-transfected
cells treated with etoposide underwent apoptosis, a percentage
essentially unchanged from the basal levels in cells treated with
DMSO. Thus, similar to our ﬁndings in 3T3 ﬁbroblasts, we ob-
served a signiﬁcant, 3-fold reduction in the percentage of apop-
totic cells in etoposide-treated cell populations in which EI24/
PIG8 levels had been suppressed.4. Discussion
EI24/PIG8, a recently-discovered, p53-induced pro-apopto-
tic factor, is frequently lost in aggressive breast cancer and ap-
pears to play a role in prevention of tumor spread in invasive
breast tumors. Loss of EI24/PIG8 may also have additional
adverse clinical consequences. We show in this report that sup-
Fig. 3. Suppression of EI24/PIG8 in MCF-7 cells results in reduced sensitivity to etoposide. (A) MCF-7 cells express etoposide-inducible EI24/PIG8.
Cells were grown on chamber slides and treated with DMSO (vehicle control) or etoposide (0.4 mM) for 24 h. Cells were ﬁxed, blocked with 5% BSA
in PBS, and stained with anti-EI24/PIG8 antibody overnight prior to application of a FITC-conjugated antibody for visualization. Etoposide, but
not DMSO vehicle control, induces EI24/PIG8, as detected by immunoﬂuorecense. (B) siRNA targeting EI24/PIG8 mRNA or negative control
siRNA, again with ﬂuorescein-tagged siRNA of irrelevant sequence (10:1 ratio), were cotransfected into MCF-7 cells and incubated for 24 h with or
without etoposide (0.4 mM). As before, qRT PCR analysis shows that EI24/PIG8 siRNA speciﬁcally and eﬀectively suppressed EI24/PIG8
induction. (C) Increased numbers of TMR-red (TUNEL)-positive cells were only observed only in the populations transfected with negative control
siRNA that were treated with etoposide. (D) Quantiﬁcation of multiple frames conﬁrms the visual images. Data are expressed as the
means ± calculated S.E.M (average number of cells counted for each condition = 2228). P-values were calculated using Student’s t-test.
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cancer cells signiﬁcantly inhibits etoposide-induced apoptosis.
Therefore, EI24/PIG8 executes its p53-controlled apoptotic
function in a species- and cell line-independent manner, in
both benign and malignant cells. Although we have not yet
fully elucidated the apoptotic molecular pathways controlled
by EI24/PIG8, which appear to be initiated at the endoplasmic
reticulum [11], the results of our studies clearly support an
important role for EI24/PIG8 in susceptibility to genotoxic
chemotherapy. While many factors play important pro- and
anti-apoptotic roles [17], and development of chemoresistance
is a complex and multifactorial process [18], the EI24/PIG8
status of tumor cells deserves to be further analyzed as a pos-
sible prognostic factor for responsiveness to cancer treatments
that utilize p53-dependent apoptosis pathways. Screening pa-
tients for the presence of EI24/PIG8 may facilitate tailoring
of unique chemotherapy drug regiments for individual pa-
tients.
Future studies are needed to examine the speciﬁc molecular
mechanisms by which EI24/PIG8 mediates p53-dependent
apoptosis. It will also be important to determine if suppressionof EI24/PIG8 mediates sensitivity to other chemotherapeutic
agents, particularly stimuli that act at discrete steps in the
apoptotic pathway. Such studies would generalize the impor-
tance of EI24/PIG8 beyond the actions of etoposide alone,
and could serve to pinpoint the location of EI24/PIG8 activity
in the apoptosis pathway.
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